<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03765944</url>
  </required_header>
  <id_info>
    <org_study_id>NPC-12T-1</org_study_id>
    <nct_id>NCT03765944</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of NPC-12 (Sirolimus) Granules and Tablets</brief_title>
  <official_title>A Single Dose, Randomized, Open-label, 2-Period, 2-way Crossover, Bioequivalence Study of Sirolimus Granules and Sirolimus Tablets in Japanese Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nobelpharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nobelpharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the bioequivalece of NPC-12 granules in compare with
      NPC-12T tablets in Japanese healthy Adults
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 5, 2018</start_date>
  <completion_date type="Actual">December 29, 2018</completion_date>
  <primary_completion_date type="Actual">December 29, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood sirolimus concentration</measure>
    <time_frame>Pre-dose and post-dose (0.5, 1, 1.5, 2, 4, 8, 12, 18, 24, 48 and 72 hours)</time_frame>
    <description>Whole blood concentration of sirolimus will be measured and compared between NPC-12 granules and NPC-12T tablets.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Bioequivalence Study</condition>
  <arm_group>
    <arm_group_label>NPC-12 granule</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>NPC-12 granules (1.0g: 2mg sirolimus)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NPC-12T tablet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>NPC-12T 2 tablets (2mg sirolimus)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sirolimus</intervention_name>
    <description>SIngle administration under fasted condition</description>
    <arm_group_label>NPC-12 granule</arm_group_label>
    <arm_group_label>NPC-12T tablet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Japanese healthy subjects aged 20 to 39 years of age

          2. Subjects with BMI â‰¥ 18.5 kg/m2 and &lt; 25.0 kg/m2

          3. Subjects who are considered by the investigator as suitable for participation in the
             trial from lab test results at screening

          4. Subjects who are considered by the investigator as suitable for participation in the
             trial from lab test results on the day before administration

          5. Subjects who write informed consent

          6. Subjects who are able to comply with the study requirements during the study period

        Exclusion Criteria:

          1. Subjects who have a history of hypersensitivity to sirolimus or sirolimus derivative

          2. Subjects who have a history of hypersensitivity or allergies to other drug

          3. SUbjects who have an acute or chronic infectious diseases

          4. Subjects who have a current or a history of disease which is considered inappropriate
             to be involved in the study, or who has any current disease to require treatments

          5. Subjects who have diagnosed with alcoholism or a history of alcoholism

          6. Subjects who have an abnormal findings (pneumonia, etc) from the result of chest CT at
             screening

          7. Subjects who have been administered other investigational drug within 12 weeks before
             the initial administration

          8. Subjects who have performed blood collection or donation as follows

               -  Collected or donated 200 ml or more whole blood within 4 weeks before the initial
                  administration

               -  Male subject; collected or donated more than 400 mL whole blood within 12 weeks
                  before the initial administration

               -  Female subjects; collected or donated more than 400 mL whole blood within 16
                  weeks before the initial administration

               -  Collected or donated blood component within 2 weeks before the initial
                  administration

          9. Subjects who have positive results for HBs antigen, HBs antibody, HBc antibody, HCV
             antibody, HIV antigen/antibody, or syphilis

         10. Subjects who received any non-prescription or prescription drug within 12 weeks before
             the initial administration

         11. Subjects who are pregnant/lactating, or do not agree to contraception during the
             period from the screening until 8 weeks after the final administration due to planning
             to become pregnant

         12. Subjects who cannot speak, read and write in Japanese

         13. Subjects who are considered by the investigator as unsuitable for participation in the
             trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Clinique Soigner</name>
      <address>
        <city>Matsudo</city>
        <state>Chiba</state>
        <zip>270 -2231</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>December 3, 2018</study_first_submitted>
  <study_first_submitted_qc>December 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 5, 2018</study_first_posted>
  <last_update_submitted>February 21, 2019</last_update_submitted>
  <last_update_submitted_qc>February 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

